The anti-BAFF mAb belimumab (HGS1006, LymphoStat-B) is the first biologic therapeutic to be approved for SLE, with approval in the United States, Canada, and Europe in 2011 [165]. The gene discussed is TNFSF13B; the disease is systemic lupus erythematosus.